Plus Therapeutics updates investor presentation

Plus Therapeutics, Inc. filed a current report noting that it has updated its corporate investor presentation for use in meetings with investors, analysts, and other stakeholders.

Rhea-AI Filing Summary

Plus Therapeutics, Inc. filed a current report noting that it has updated its corporate investor presentation for use in meetings with investors, analysts, and other stakeholders. The updated materials are provided as an exhibit labeled an investor presentation as of January 22, 2026.

The company indicates that these slides are intended to support discussions about its business with the financial community and others by providing a refreshed overview in a single document.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Plus Therapeutics (PSTV) disclose in this 8-K?

Plus Therapeutics disclosed that it updated its corporate investor presentation and made certain updated slides available as an exhibit labeled an investor presentation as of January 22, 2026.

How will Plus Therapeutics (PSTV) use the updated investor presentation?

The updated investor presentation is intended for use in meetings with investors, analysts, and others to communicate information about Plus Therapeutics and its business.

Where can investors find the new Plus Therapeutics (PSTV) presentation?

Investors can find the new materials in the exhibit section identified as Investor Presentation as of January 22, 2026 (Exhibit 99.1).

Does this Plus Therapeutics (PSTV) update involve any major transaction or earnings data?

The disclosure focuses on an updated investor presentation; it does not describe any major transaction or provide earnings data in the text provided.

Who signed the Plus Therapeutics (PSTV) report about the investor presentation?

The report was signed on behalf of Plus Therapeutics by Marc H. Hedrick, M.D., President and Chief Executive Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/22/2026 - 07:30 AM Learn about SEC filing dates

NASDAQ false 0001095981 0001095981 2026-01-22 2026-01-22

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 22, 2026

PLUS THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-34375		33-0827593
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

6420 Levit Green Boulevard, Suite 310

Houston, Texas 77021

(Address of principal executive offices, with zip code)

(737) 255-7194

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001		PSTV		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On January 22, 2026, Plus Therapeutics, Inc. updated its corporate presentation for use in meetings with investors, analysts and others. A copy of certain updated slides is filed as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Investor Presentation as of January 22, 2026.
104		Cover Page Interactive Data File (formatted in Inline XBRL in Exhibit 101).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 22, 2026

PLUS THERAPEUTICS, INC.
By:		/s/ Marc H. Hedrick, M.D.
		Marc H. Hedrick, M.D.
		President and Chief Executive Officer